FDA says Geodon journal ad omits risk info

Share this article:
The FDA says a professional journal ad for Pfizer's antipsychotic medication Geodon (ziprasidone mesylate) for injection omits important risk info and contains unsubstantiated superiority claims. It wants the company to submit a list of all materials to be pulled along with a plan for discontinuing its use, and Pfizer has agreed.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.